Unveiling the functional outcome of single nucleotide polymorphisms and variants in oligodendroglia in multiple sclerosis
This project aims to explore the active role of oligodendroglia in multiple sclerosis by analyzing SNPs/variants through single-cell omics and CRISPR editing to identify therapeutic targets.
Projectdetails
Introduction
Multiple sclerosis (MS) is a neurological disease characterized by autoimmune attack targeting oligodendroglia (OLG) in the central nervous system (CNS), and in particular their myelin, which ensheaths neuronal axons. Genome-wide association studies (GWAS) have led to the identification of hundreds of single-nucleotide polymorphisms (SNPs) and variants that are associated with MS risk.
Role of Immune Cells
Many of these SNPs/variants are located near genes associated with immune cells, indicating a key role for these cells in MS. Using single-cell omics approaches, we recently found that OLG present chromatin accessibility or express genes associated with some of these SNPs/variants, both in health and disease.
Hypothesis and Objectives
Here, we hypothesize that OLG have a more active role in MS than previously anticipated. Therefore, we will determine the function of MS SNPs/variants in OLG in the context of MS, using humanized mouse models, patient samples, and new single-cell omics techniques recently developed in my group.
Specific Aims
We will:
- Characterize in-depth the transcriptomic and epigenomic landscape of human and mouse OLG in the context of MS, to identify putative genes affected by the SNPs/variants.
- Perform CRISPR-guided editing of a cohort of the identified SNPs/variants in human OLG, and determine the consequences of the editing at: a) An epigenomic and transcriptional level, linking specific SNPs/variants to their bona-fide target genes. b) A functional level, by performing an array of functional assays targeting myelination, cell survival, and immune function, both in vitro and in humanized mouse chimeras in which engineered human OLG have been transplanted.
Methodology
We will use single-cell and spatial omics technologies, such as nanoCUT&Tag and spatial CUT&Tag, among others which we have recently developed in my research group.
Expected Outcomes
The results of this project will yield unique insights into the role of OLG and the identified SNPs/variants in MS, and thereby pave the way to novel therapeutic avenues for this disease.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 3.182.846 |
Totale projectbegroting | € 3.182.846 |
Tijdlijn
Startdatum | 1-1-2024 |
Einddatum | 31-12-2028 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- KAROLINSKA INSTITUTETpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Uncovering the molecular mechanisms of oligodendrocyte plasticity in cognitive aging.This project aims to investigate oligodendrocyte plasticity and its role in cognitive decline with aging, using advanced techniques to identify therapeutic targets for brain rejuvenation. | ERC Starting... | € 1.498.665 | 2024 | Details |
Deciphering the microglia-neuron interactions in human Alzheimer's diseaseThis project aims to elucidate how human microglia contribute to neuronal toxicity in Alzheimer's disease using a pioneering xenograft model to explore their interactions and secretome. | ERC Starting... | € 1.500.000 | 2023 | Details |
Multi-omics characterization of immune triggers in Moyamoya diseaseThe project investigates the link between immune responses to infections and the onset of Moyamoya disease in RNF213 mutation carriers using a multi-omics approach to uncover underlying mechanisms. | ERC Consolid... | € 1.981.593 | 2023 | Details |
Elucidating and targeting the mechanisms encoded in the genome of long-lived individuals to improve healthy ageingThis project aims to identify and validate rare genetic variants linked to longevity using CRISPR/Cas9 and high-throughput screening to promote healthy aging and extend lifespan. | ERC Starting... | € 1.500.000 | 2022 | Details |
Do T cells link loss and gain-of-function mechanism in C9orf72 ALS/FTD?This project investigates the role of T cells in the pathogenesis of ALS and FTD due to C9orf72 mutations, aiming to uncover mechanisms for new biomarkers and therapeutic targets. | ERC Starting... | € 1.498.610 | 2024 | Details |
Uncovering the molecular mechanisms of oligodendrocyte plasticity in cognitive aging.
This project aims to investigate oligodendrocyte plasticity and its role in cognitive decline with aging, using advanced techniques to identify therapeutic targets for brain rejuvenation.
Deciphering the microglia-neuron interactions in human Alzheimer's disease
This project aims to elucidate how human microglia contribute to neuronal toxicity in Alzheimer's disease using a pioneering xenograft model to explore their interactions and secretome.
Multi-omics characterization of immune triggers in Moyamoya disease
The project investigates the link between immune responses to infections and the onset of Moyamoya disease in RNF213 mutation carriers using a multi-omics approach to uncover underlying mechanisms.
Elucidating and targeting the mechanisms encoded in the genome of long-lived individuals to improve healthy ageing
This project aims to identify and validate rare genetic variants linked to longevity using CRISPR/Cas9 and high-throughput screening to promote healthy aging and extend lifespan.
Do T cells link loss and gain-of-function mechanism in C9orf72 ALS/FTD?
This project investigates the role of T cells in the pathogenesis of ALS and FTD due to C9orf72 mutations, aiming to uncover mechanisms for new biomarkers and therapeutic targets.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
SLIMS: Scherpe Laesie Identificatie in Multiple ScleroseHet SLIMS platform ontwikkelt innovatieve methoden voor vroege MS-diagnose en verbeterde behandeling, ter verhoging van de levenskwaliteit. | Mkb-innovati... | € 171.500 | 2020 | Details |
Revolutionising the diagnosis of multiple Sclerosis with the first bioinformatic diagnostic kit that allows early detection with a simple blood testALA DIAGNOSTICS aims to revolutionize multiple sclerosis diagnosis with a fast, non-invasive blood test using a patented biomarker, reducing misdiagnoses and improving patient outcomes. | EIC Accelerator | € 1.407.525 | 2023 | Details |
SLIMS: Scherpe Laesie Identificatie in Multiple Sclerose
Het SLIMS platform ontwikkelt innovatieve methoden voor vroege MS-diagnose en verbeterde behandeling, ter verhoging van de levenskwaliteit.
Revolutionising the diagnosis of multiple Sclerosis with the first bioinformatic diagnostic kit that allows early detection with a simple blood test
ALA DIAGNOSTICS aims to revolutionize multiple sclerosis diagnosis with a fast, non-invasive blood test using a patented biomarker, reducing misdiagnoses and improving patient outcomes.